Eurofins is making new assays for the identification of B.1.1.7 (UK) and B.1.351 (South Africa)/B.1.1.248 (Brazil) variants with a one hour run time available for free to public health institutions who do not have capabilities to rapidly identify the presence of these variants.

SARS-CoV-2 belongs to a group of RNA viruses that exhibit spontaneous mutations. Some alarming variants have recently been identified including: The new lineage B.1.1.7 first identified in South England and the lineages B.1.351 and B.1.1.248 initially discovered in South Africa and Brazil, respectively. All of these variants appear to be more infective.

Next Generation Sequencing (NGS) is generally used for detecting new mutations of the virus as part of epidemiological studies. However, NGS typically takes three to five days. This is often too slow to identify carriers of the new variants so that their contacts can be isolated and tested as a matter of priority to stop the spread of these variants in regions where they are not yet prevalent.

Eurofins Technologies and Eurofins Genomics now offer kits and primer and probes sets to identify the new variants. The GSD NovaType SARS-CoV-2 Detect & ID available in Europe only is a Real-Time RT-PCR test for the qualitative detection of SARS-CoV-2, and the subsequent identification of B.1.1.7 and B.1.351/B.1.1.248 variants. The product has been validated as a two-step workflow with a CE-IVD marked diagnostic test followed by an identification step (Research Use Only “RUO”). Alternatively, laboratories can choose to request just the RUO identification kit GSD NovaType SARS-CoV-2 ID.

Eurofins’ global network of clinical laboratories is continuously monitoring the emergence of additional SARS-CoV-2 variants of concern and expects to be at the forefront of launching additional kits to detect those due to its unique integration of capabilities across laboratory testing, primer and probe design as well as IVD kit development. An updated version of NovaType able to detect and distinguish additional variants is expected to be released mid-February.

To request free kits, contact the Eurofins Foundation at EmilieFillod@eurofins.com. For technical information, please visit this page.

For more information, please visit www.eurofins.com or contact:

Investor Relations Eurofins Scientific SE Phone: +32-2-766 1620 E-mail: ir@eurofins.com

Notes for the editor:

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is a global leader in food, environment, pharmaceutical and cosmetic product testing and in agroscience Contract Research Organisation services. Eurofins is one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in the support of clinical studies, as well as having an emerging global presence in Contract Development and Manufacturing Organisations. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With over 50,000 staff across a decentralised and entrepreneurial network of more than 800 laboratories in over 50 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

The Group’s objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.

In 2020, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity for over 10 million patient tests per month to support efforts to identify and suppress the virus. The Group has established widespread PCR testing capabilities and has carried out over 10 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments during COVID-19.

Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.